Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality

Canadian Journal of Public Health

Volumn 99, Issue 5, 2008, Pages 383-386

  Brisson, Marc ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Herpes zoster (HZ); Mathematical model; Number needed to vaccinate; Post herpetic neuralgia (PHN); Vaccines

Indexed keywords

EID: 56049083238     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405246     Document Type: Article

References (20)

1. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571-75.
2. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005;18:70-80.
3. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes Zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
4. Watson CP. Management issues of neuropathic trigeminal pain from a medical perspective. J Orofac Pain 2004;18:366-73.
5. Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis 2002;186(Suppl 1):S83-S90.
6. Oxman MN, Levin MJ, Johnson GR, Schmader K, and Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352;2271-84.
7. Laupacis A, Sackett DL, Roberts DS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
8. Skootsky SA. Live attenuated Varicella-Zoster vaccine: Is it worth it? Proceedings of UCLA Healthcare 2006;10:1-3.
9. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. Potential cost-effectiveness of vaccination against Herpes Zoster and PHN in Canada. Hum Vaccine 2008;4:238-45.
10. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305-14.
11. Canadian Institute for Health Information (CIHI). Hospital Morbidity Database (HMDB), 2000-2003.
12. Statistics Canada. Complete life table, Canada, 2000 to 2002. Available online at: http://www.statcan.cal (Accessed August 26, 2008).
13. Brisson M, Johnson RW, Levin MJ, Oxman MN, Schmader KE, Patrick DM, et al. Measuring Herpes Zoster (HZ) and Post-Herpetic Neuralgia (PHN) associated burden of illness, health care utilization and costs in Canada: A clinical epidemiological study. Can J Infect Dis Med Microbiol 2006;17(6):381.
14. Brisson M, Van de Velde N, Boily MC, De Wals P. Estimating the number needed to treat to vaccinate to prevent HPV related disease and mortality. CMAJ 2007;177(5):464-68.
15. Advisory Committee on Immunization Practices. Considerations for shingles vaccine recommendations in the U.S.: Record of the proceedings. Atlanta, GA: Centers for Disease Control and Prevention, 2006. Available online at: http://www.cdc.gov/nip/acip/minutes/acip-min-jun06.pdf (Accessed March 12, 2007).
16. Kelly H, Attia J, Andrews R, Heller RF. The number needed to vaccinate (NNV) and population extensions of the NNV: Comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004;22:2192-98.
17. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002;20(7-8):1113-25.
18. Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol 2003;70(Suppl 1):S9-S14.
19. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute Herpes Zoster: Healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007;25(2):155-69.
20. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: Cost-utility analysis. Arch Dis Child 2003;88:862-69.